Celsion’s extensive oncology pipeline represents a comprehensive, integrated portfolio of targeted therapeutic agents, encompassing chemotherapy, immunotherapy, and RNA therapy.
ThermoDox®, Celsion’s lead product candidate, incorporates Lyso-Thermosenstive Liposomal Doxorubicin (LTLDs), a unique liposomal technology that allows for the triggered release of a drug payload through low temperature (just above body temperature) heat activation.
TheraPlas™ is a versatile technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers and is uniquely capable of providing cell transfection capability for double-stranded DNA plasmids and large therapeutic RNA segments such as mRNA.
TheraSilence™ is a versatile technology platform focused on delivering synthetically generated small inhibitory RNAs (siRNAs), microRNAs, microRNA mimics, and related molecules that can regulate protein expression by exploiting endogenous cell mechanisms.
Celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. With the recent acquisition of EGEN, Inc., Celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer DNA/RNA therapies; and expertise from bench to bedside.